NRX Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . NRX Pharmaceuticals
NRXP Stock  USD 2.17  0.12  5.85%   
NRX Pharmaceuticals financial statements provide useful quarterly and yearly information to potential NRX Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NRX Pharmaceuticals financial statements helps investors assess NRX Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NRX Pharmaceuticals' valuation are summarized below:
Market Capitalization
39.8 M
Earnings Share
(2.11)
There are currently one hundred twenty fundamental ratios for NRX Pharmaceuticals that can be evaluated and compared over time across peers in the industry. Investors and active traders are advised to check NRX Pharmaceuticals' last-minute fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/18/2025, Market Cap is likely to drop to about 22 M. In addition to that, Enterprise Value is likely to drop to about 20.6 M
Check NRX Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRX Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 372.8 K, Interest Expense of 131.1 K or Selling General Administrative of 20.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRX financial statements analysis is a perfect complement when working with NRX Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NRX Pharmaceuticals Correlation against competitors.
To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.

NRX Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets6.3 M6.6 M46.3 M
Slightly volatile
Other Current Liabilities9.7 M6 M4.8 M
Slightly volatile
Total Current Liabilities14.9 M21.9 M8.3 M
Slightly volatile
Accounts Payable5.6 M5.3 M1.6 M
Slightly volatile
Cash8.6 M5.3 M4.5 M
Slightly volatile
Non Current Assets Total368.5 K387.9 K41 M
Slightly volatile
Cash And Short Term Investments8.6 M5.3 M4.5 M
Slightly volatile
Common Stock Total Equity2.3 K2.4 K37.8 M
Slightly volatile
Common Stock Shares Outstanding8.3 M8.7 M12.2 M
Slightly volatile
Short Term Investments5.1 M5.4 M43.1 M
Slightly volatile
Liabilities And Stockholders Equity6.3 M6.6 M46.3 M
Slightly volatile
Capital Surpluse3.5 M2.5 M4.2 M
Slightly volatile
Other Current Assets3 M2.6 M1.6 M
Slightly volatile
Other Stockholder Equity291.4 M277.5 M85.4 M
Slightly volatile
Total Liabilities15.7 M21.9 M8.6 M
Slightly volatile
Total Current Assets10.8 M7.9 M5.7 M
Slightly volatile
Common Stock71.8 K75.6 K37.8 M
Slightly volatile
Short and Long Term Debt Total11.1 M10.5 M3.2 M
Slightly volatile
Long Term Debt2.2 M3.2 M1.5 M
Slightly volatile
Short and Long Term Debt11.1 M10.5 M2.6 M
Slightly volatile
Capital Stock70.4 K100 K53.5 K
Slightly volatile
Short Term Debt11.1 M10.5 M2.6 M
Slightly volatile
Current Deferred Revenue2.3 M2.6 M2.8 M
Slightly volatile

NRX Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative20.3 M16.3 M10.4 M
Slightly volatile
Depreciation And Amortization4.3 K4.5 K613.9 K
Slightly volatile
Other Operating Expenses32.9 M31.7 M15.7 M
Slightly volatile
Cost Of Revenue4.3 K4.5 K680.8 K
Slightly volatile
Total Operating Expenses32.9 M31.7 M15.7 M
Slightly volatile
Research Development13.5 M15.4 M5.6 M
Slightly volatile
Reconciled Depreciation3.6 K5.8 K2.6 K
Slightly volatile
Selling And Marketing Expenses4 K4.5 K4.9 K
Slightly volatile

NRX Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow8.6 M5.3 M4.5 M
Slightly volatile
Begin Period Cash Flow24.2 M23.1 M6.4 M
Slightly volatile
Stock Based Compensation422.8 K445.1 K837.9 K
Slightly volatile
Depreciation6 K5.8 K1.5 K
Slightly volatile
Change To Netincome39.4 M69.3 M21.8 M
Slightly volatile
Cash And Cash Equivalents Changes368414451
Slightly volatile
Issuance Of Capital Stock19.7 M10.8 M8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables1.5 M1.7 M1.9 M
Slightly volatile
Capex To Depreciation0.660.693.3
Slightly volatile
Payables Turnover0.00120.00121.0637
Slightly volatile
Cash Per Share0.130.137247.46
Slightly volatile
Days Payables Outstanding635.9 K605.6 K204 K
Slightly volatile
Current Ratio0.140.1513.2022
Slightly volatile
Capex Per Share4.0E-44.0E-41.0E-4
Slightly volatile
Interest Debt Per Share0.02080.02190.7661
Pretty Stable
Debt To Assets1.181.130.2753
Slightly volatile
Graham Number17.529.1219.4352
Slightly volatile
Days Of Payables Outstanding635.9 K605.6 K204 K
Slightly volatile
Effective Tax Rate3.0E-43.0E-40.1912
Pretty Stable
Quick Ratio0.140.1513.2019
Slightly volatile
Net Income Per E B T0.60.90.7776
Very volatile
Cash Ratio0.06270.0662.6587
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0157
Slightly volatile
Debt Ratio1.181.130.2753
Slightly volatile

NRX Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap22 M23.1 M1.7 B
Slightly volatile
Enterprise Value20.6 M21.7 M1.7 B
Slightly volatile

NRX Fundamental Market Drivers

Cash And Short Term Investments4.6 M

NRX Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
21st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About NRX Pharmaceuticals Financial Statements

NRX Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although NRX Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in NRX Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on NRX Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.6 M2.3 M
Cost Of Revenue4.5 K4.3 K

Additional Tools for NRX Stock Analysis

When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY